Table 1 Descriptive statistics of the study sample.

From: Association between cumulative exposure periods of flupentixol or any antipsychotics and risk of lung cancer

 

Case, no. (%)

Control, no. (%)

Patients, no.

6435

64,348

Gender

  Female

2313 (35.94)

23,130 (35.95)

  Male

4122 (64.06)

41,218 (64.05)

Age

  18–24

0

0

  25–44

104 (1.62)

1040 (1.62)

  45–64

1514 (23.53)

15140 (23.53)

  65–84

3409 (52.98)

34090 (52.98)

  85+

1408 (21.88)

14078 (21.88)

  Mean (SD), y

73.60 (12.79)

73.59 (12.79)

Previous medications

  NSAIDs

3694 (57.40)

31485 (48.93)

  Statins

1768 (27.47)

17729 (27.55)

  Aspirin

2432 (37.79)

25327 (39.36)

  Metformin

1082 (16.81)

12280 (19.08)

Comorbidities

  Tobacco use

72 (1.12)

502 (0.78)

  Diabetes

1134 (17.62)

12,636 (19.64)

  COPD

1144 (17.78)

6086 (9.46)

  Hypertension

2205 (34.27)

22,995 (35.74)

  Hyperlipidemia

706 (10.97)

6719 (10.44)

  Cirrhosis

128 (1.99)

1113 (1.73)

  CKD

160 (2.49)

1809 (2.81)

  Peptic ulcer

45 (0.70)

417 (0.65)

  Pneumonia

2188 (34.00)

12,507 (19.44)

  Schizophrenia

645 (10.02)

12,795 (19.88)

  Depressive disorders

649 (10.09)

8633 (13.42)

  Anxiety disorders

147 (2.28)

2214 (3.44)

  Bipolar disorders

94 (1.46)

2028 (3.15)

  Personality disorders

52 (0.81)

783 (1.22)

  Delusional disorders

158 (2.46)

3008 (4.82)

  Other nonorganic psychoses

435 (6.76)

5177 (8.29)

  Dementia

1106 (17.19)

18,218 (28.31)

  1. NSAIDs non-steroidal anti-inflammatory drugs, COPD chronic obstructive pulmonary diseases, CKD chronic kidney disease.